Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | MB | P02144 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463078 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL19806131 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL4048000 | 0.82 | ALDH1A1 (0.53) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL104524 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL11112670 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL8528686 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL4986450 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL11989512 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL8643836 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL4579197 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL1HTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
| US-20020115653-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6319939-B1 | P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-20 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0260744-B1 | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| US-4859684-A | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-22 | — | — | US | disclosed |
| EP-0260744-A2 | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115653-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | SMN1; SMN2 2646/4885L3MBTL1 2635/4885HTT 2464/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | SMN1; SMN2 3050/4885L3MBTL1 2107/4885HTT 2246/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | SMN1; SMN2 3061/4885L3MBTL1 1987/4885HTT 2206/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | SMN1; SMN2 3050/4885L3MBTL1 2107/4885HTT 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.